Spectrum Pharmaceuticals ranked #23 on Deloitte's Technology Fast 500

Spectrum Pharmaceuticals, Inc. (NasdaqGM:SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that it ranked #23 on Technology Fast 500™, Deloitte's ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Rankings are based on percentage of fiscal year revenue growing during the period from 2005-2009. Spectrum Pharmaceuticals grew 6,490% during this period.

“Deloitte commends Spectrum for this impressive accomplishment.”

"We are pleased to once again be ranked one of the fastest growing companies in North America," said Rajesh C. Shrotriya, MD, Chairman of the Board of Directors, Chief Executive Officer, and President of Spectrum Pharmaceuticals. "We believe that product revenues from ZEVALIN and FUSILEV will continue to be strong, and would expect to remain on the Deloitte Technology Fast 500™ list of growing companies in North America for the next several years."

"Spectrum Pharmaceuticals and the other 2010 Technology Fast 500™ winners forged ahead in a challenging economic environment to realize exceptional growth," said Phil Asmundson, vice chairman and Deloitte's U.S. technology, media and telecommunications leader. "Deloitte commends Spectrum for this impressive accomplishment."

Overall, Technology Fast 500™ award winners for 2010 had revenue growth ranging from 146 percent to 164,079 percent from 2005 to 2009, with an average growth of 2,361 percent.